sur Moderna, Inc. (NASDAQ:MRNA)
Moderna delivers first Canadian-made mRNA vaccines
Moderna has announced the shipment of the first mRNA vaccines manufactured in Canada to various provinces and territories. This milestone marks a significant step forward in the country's vaccine production autonomy, strengthening its health security. The vaccines are produced in Laval, Quebec, with packaging carried out in Ontario by Novocol Pharma.
The vaccine targeting the SARS-CoV-2 LP.8.1 variant received Health Canada approval on August 21, 2025, as well as international approvals. Moderna is pursuing global regulatory submissions for the upcoming respiratory virus season.
Each province will determine its own vaccination schedule and eligibility criteria, ensuring free access to eligible individuals. Discussions are underway with the private sector to ensure broader access.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Moderna, Inc.